Markers of Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: New in Molecular Oncology.

Q2 Medicine Asian Pacific Journal of Cancer Prevention Pub Date : 2024-11-01 DOI:10.31557/APJCP.2024.25.11.3761

Ekaterina Kravtsova, Matvey Tsyganov, Irina Tsydenova, Daria Dolgasheva, Ksenia Gaptulbarova, Nikolai Litviakov, Marina Ibragimova

{"title":"Markers of Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: New in Molecular Oncology.","authors":"Ekaterina Kravtsova, Matvey Tsyganov, Irina Tsydenova, Daria Dolgasheva, Ksenia Gaptulbarova, Nikolai Litviakov, Marina Ibragimova","doi":"10.31557/APJCP.2024.25.11.3761","DOIUrl":null,"url":null,"abstract":"<p><p>It is known that complete pathomorphological response (pCR) after neoadjuvant therapy (NAC) in patients with breast cancer (BC) correlates with higher rates of recurrence-free and overall survival. In turn, the widespread use of neoadjuvant therapy for the treatment of breast cancer defines the clinical need for prognostic markers of response to ongoing therapy. Currently, some clinicopathological prognostic factors are used to assess the potential benefit of neoadjuvant systemic therapy for female patients, but they have limited applicability. In the era of precision medicine and personalised treatment, a search for new prognostic markers is needed to better tailor patient-specific therapy. To date, novel factors have been proposed to predict response to preoperative treatment in breast cancer patients, but they are either not yet used in routine clinical practice or have limited application. Thus, this review summarises data on both established and proven biomarkers and the latest prognostic factors for response to neoadjuvant treatment in breast cancer patients.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"25 11","pages":"3761-3769"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2024.25.11.3761","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

It is known that complete pathomorphological response (pCR) after neoadjuvant therapy (NAC) in patients with breast cancer (BC) correlates with higher rates of recurrence-free and overall survival. In turn, the widespread use of neoadjuvant therapy for the treatment of breast cancer defines the clinical need for prognostic markers of response to ongoing therapy. Currently, some clinicopathological prognostic factors are used to assess the potential benefit of neoadjuvant systemic therapy for female patients, but they have limited applicability. In the era of precision medicine and personalised treatment, a search for new prognostic markers is needed to better tailor patient-specific therapy. To date, novel factors have been proposed to predict response to preoperative treatment in breast cancer patients, but they are either not yet used in routine clinical practice or have limited application. Thus, this review summarises data on both established and proven biomarkers and the latest prognostic factors for response to neoadjuvant treatment in breast cancer patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

预测乳腺癌新辅助化疗反应的标志物：分子肿瘤学的新进展。

众所周知，乳腺癌（BC）患者新辅助治疗（NAC）后的完全病理形态学反应（pCR）与更高的无复发率和总生存率相关。反过来，新辅助治疗在乳腺癌治疗中的广泛应用决定了对持续治疗反应的预后标志物的临床需求。目前，一些临床病理预后因素被用来评估女性患者新辅助全身治疗的潜在益处，但它们的适用性有限。在精准医疗和个性化治疗的时代，需要寻找新的预后标记物来更好地定制针对患者的治疗。迄今为止，已经提出了新的因素来预测乳腺癌患者术前治疗的反应，但它们要么尚未用于常规临床实践，要么应用有限。因此，本综述总结了乳腺癌患者对新辅助治疗反应的已建立和已证实的生物标志物和最新预后因素的数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.